Revefenacin

瑞维那新

Report date: 2026/03/06 20:02:51
NME

Base Information

Drug NameRevefenacin
Drug Alias Namerevefenacina瑞维那新瑞非那新revefenacinum雷芬那辛 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor antagonists
TargetsMuscarinic acetylcholine receptor
Therapy Area/IndicationsRenal InsufficiencyRespiratory InsufficiencyPulmonary Disease, Chronic Obstructive +[4] 
Global Approved IndicationsPulmonary Disease, Chronic Obstructive
Approved Indications in ChinaPulmonary Disease, Chronic Obstructive
Original Approved Country/TerritoryUnited States
Original Approved Date2018/11/09
Country/TerritoryUnited StatesNew ZealandUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTheravance Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesTheravance Biopharma IncMylan Pharmaceuticals IncMylan Ireland Ltd +[4] 
Inactive CompaniesMylan Pharma Uk LtdGlaxosmithkline PlcMylan Inc +[5] 
Active IndicationsRespiratory InsufficiencyPulmonary Disease, Chronic Obstructive
Inactive IndicationsRenal InsufficiencyHepatic Insufficiency

Other Information

ATC CodeR03BB08
Related LinksDrugBankKEGG